Phase IB/II Open-label Single Arm Study to Evaluate Safety and Efficacy of Tucatinib in Combination With Palbociclib and Letrozole in Subjects With Hormone Receptor Positive and HER2-positive Metastatic Breast Cancer

Trial Profile

Phase IB/II Open-label Single Arm Study to Evaluate Safety and Efficacy of Tucatinib in Combination With Palbociclib and Letrozole in Subjects With Hormone Receptor Positive and HER2-positive Metastatic Breast Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs Letrozole (Primary) ; Palbociclib (Primary) ; Tucatinib (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TULiP
  • Most Recent Events

    • 07 Dec 2017 According to a Cascadian Therapeutics media release, trial design presented at the 2017 San Antonio Breast Cancer Symposium (SABCS).
    • 07 Dec 2017 According to a Cascadian Therapeutics media release, this trial is currently opened for enrollment at the University of Colorado Denver, and soon will be opened at five additional academic institutions (members of Academic Breast Cancer Research Consortium): North Western University, Chicago, IL; University of Texas Health and Science Center at San Antonio, TX; Stony Brook University, NY; University of Arizona, Tucson, AZ, and University of New Mexico, Albuquerque, NM.
    • 07 Dec 2017 Status changed from not yet recruiting to recruiting according to a Cascadian Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top